Dr. Patricia J. McLaughlin, Ph.D.
Dr. McLaughlin received her post-baccalaureate training at Penn State University and began working in the laboratory with Dr. Zagon in the mid-1970s. In collaboration with Dr. Ian Zagon, Dr. McLaughlin first discovered the exciting effects of LDN in 1979, and published a seminal paper in Science in 1983 describing the potential benefits of LDN.
Dr. McLaughlin's work focuses on translational research, and the OGF-OGFr axis and its working mechanisms in both normal and disease states. By examining negative modulators of cancerous growth, not promoters, and attempting to understand the negative signaling pathways mediated by the OGF-OGFr axis during the cycle progression of cancer cells, her work provides an understanding of how cancer develops and progresses. This research is valuable in aiding the development of cancer treatment. It also benefits future studies focusing on the use of gene therapy for re-introduction of OGFr into neoplastic tissues, and preclinical and clinical trials using OGF as a biotherapy by itself and in combination with other chemotherapies.
Dr. McLaughlin is currently a tenured professor, Director of the Anatomy Graduate Program at the College of Medicine, and heads laboratory research on the use of OGF and LDN in cancer, multiple sclerosis, and diabetic-associated wound healing.
To learn more about her bio, click on Dr. Patricia McLaughlin's profile
To view her work, click on Dr. Patricia McLaughlin’s Work
MedInsight® Research Institute.
All rights reserved.
About LDNscience®
LDNscience® is a public information project of the MedInsight® Research Institute.
MedInsight® Research Institute is a U.S./U.K. based non-profit organization which serves as a platform for researching and indexing available off-label (repurposed) treatments for cancer and chronic diseases.
MedInsight's Projects:
Dipyridamole Eye Drops
Cureiosity®
